The new $1.5 billion funding agreement will support the clinical development of an investigational monthly injection being studied for chronic weight management and obesity-related comorbidities, including OSA.
Key takeaways:
Blackstone Life Sciences will provide Pfizer up to $1.5 billion through 2028 to fund development costs for berobenatide. ...